National strategy for drugs for rare disease update

$1.5 billion in funding over three years announced to help increase access to, and affordability of, effective drugs for rare diseases.

The NMD4C are pleased to share that in March Health Canada announced a new funding plan to support the first-ever national strategy for drugs for rare disease, with an investment of $1.5 billion over three years. This national strategy will increase access to, and affordability of, effective drugs for rare diseases to improve the health of patients across Canada.

 

Background consultation

The national strategy for drugs for rare disease is the result of an extensive consultation with the rare disease community by Health Canada, the outcomes of which were published in the ‘What We Heard’ report in July 2021. This engagement saw more than 650 individuals and organizations in the rare disease community including patients with lived experience, family members, and caregivers, share their views and ideas towards a national drugs for rare diseases strategy. NMD4C together with Muscular Dystrophy Canada and Defeat Duchenne Canada (formerly Jesse’s Journey) submitted a letter in response to this consultation.

 

National Strategy for Drugs for Rare Diseases

The recently announced national strategy will work to directly improve access to new and emerging drugs, enhance access to existing drugs, and support early diagnosis and screening for rare diseases. The strategy includes various initiatives to help improve consistent access to drugs for rare diseases across the country, including: cost-sharing of new and emerging drugs, improved evidence collection to support decision-making, enhanced diagnostic tools, funding for Indigenous Services Canada’s Non-Insured Health Benefits Program, and the establishment of a Canadian rare disease clinical trials network.

As a network serving the neuromuscular disease community in Canada, many of our activities align with the new national strategy, particularly our work to strengthen the Canadian neuromuscular clinical trial capacity and provide access to innovative therapies and treatments for all Canadians. We are grateful to support and advocate for the Canadian neuromuscular disease community towards raising the standard of care for neuromuscular diseases and access to therapies across Canada, and look forward to the implementation of these initiatives from Health Canada as a part of a broader national strategy.

 

Links

  • Official National strategy for drugs for rare disease news release from Health Canada
  • Press release from Muscular Dystrophy Canada in response to Health Canada’s announcement.
  • Press release from Defeat Duchenne Canada in response to Health Canada’s announcement.
  • Press release from Canadian Organization for Rare Disorders (CORD) in response to Health Canada’s announcement.
  • Results from the Health Canada consultation with the rare disease community to inform this strategy.
Update to national strategy for drugs for rare diseases

Read next...

2025 clinical and research fellowships competition from NMD4C and MDC.

Fourth Annual Clinical & Postdoctoral Fellowship Competition from NMD4C, MDC to Open Fall 2024

NMD4C together with Muscular Dystrophy Canada are excited to announce that our annual Neuromuscular Fellowship Competition will open again for a fourth year on September 3, 2024!

NMD4C wraps up 2023-2024 neuromuscular clinical training curriculum

NMD4C Wraps up Second Year of Training Series for Canadian Neuromuscular Clinical Fellows

We’re excited to share that the second annual National Neuromuscular Lecture Series (NNLS) finished last week!

2024 NMD4C basic research summer school. Photo of attendees on the right.

NMD4C Host Inaugural Basic Research Summer School

Over May 27-28 2024, the NMD4C animal and cell-based research team hosted the first-ever annual basic research summer school for neuromuscular research trainees at McGill University in Montréal, QC. 

NMD4C investigator Dr Reshma Amin receives funding from CIHR for a grant to develop a framework for real-world evidence for NMDs in Canada

NMD4C Investigator Dr. Reshma Amin Leads Successful CIHR Grant Application to Establish a Framework for Real-World Evidence for Canadian Neuromuscular Diseases

Real-World Evidence for Canadian Neuromuscular Disease: Establishing a Framework for National Integration of Patient Reported Outcomes, Clinical Registry Data, Healthcare Utilization and Healthcare Associated Costs   The NMD4C is excited to share that network investigator Dr. Reshma Amin has been awarded funding from the CIHR to establish a framework for real-world evidence (RWE) for Canadian…

Spinal muscular atrophy outcome measures training registration open for December 3rd event.

Spinal Muscular Atrophy Outcome Measures Workshop (English Language)

The NMD4C will be hosting an English-language interactive training workshop on standardizing assessment practices in SMA outcome measures. 

Canadian Neuromuscular Community of Practice

NMD4C Launch Survey to Assess Familiarity and Experience in Outcome Measures in NMDs

As we anticipate novel treatments for other neuromuscular conditions, we would like to understand your familiarity and experience with the outcome measures in clinical trials underway or for treatments for NMDs approved in other jurisdictions through a short survey.